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Abstract
Background: Conflicting data exist regarding the prognostic and predictive impact of survivin (BIRC5) in breast
cancer. We previously reported survivin cytoplasmic-to-nuclear ratio (CNR) as an independent prognostic indicator
in breast cancer. Here, we validate survivin CNR in a separate and extended cohort. Furthermore, we present new
data suggesting that a low CNR may predict outcome in tamoxifen-treated patients.
Methods: Survin expression was assessed using immunhistochemistry on a breast cancer tissue microarray (TMA)
containing 512 tumours. Whole slide digital images were captured using an Aperio XT scanner. Automated image
analysis was used to identify tumour from stroma and then to quantify tumour-specific nuclear and cytoplasmic
survivin. A decision tree model selected using a 10-fold cross-validation approach was used to identify prognostic
subgroups based on nuclear and cytoplasmic survivin expression.
Results: Following optimisation of the staining procedure, it was possible to evaluate survivin protein expression in
70.1% (n = 359) of the 512 tumours represented on the TMA. Decision tree analysis predicted that nuclear, as
opposed to cytoplasmic, survivin was the most important determinant of overall survival (OS) and breast cancer-
specific survival (BCSS). The decision tree model confirmed CNR of 5 as the optimum threshold for survival analysis.
Univariate analysis demonstrated an association between a high CNR (>5) and a prolonged BCSS (HR 0.49, 95% CI
0.29-0.81, p = 0.006). Multivariate analysis revealed a high CNR (>5) was an independent predictor of BCSS (HR 0.47,
95% CI 0.27-0.82, p = 0.008). An increased CNR was associated with ER positive (p = 0.045), low grade (p = 0.007),
Ki-67 (p = 0.001) and Her2 (p = 0.026) negative tumours. Finally, a high CNR was an independent predictor of OS
in tamoxifen-treated ER-positive patients (HR 0.44, 95% CI 0.23-0.87, p = 0.018).
Conclusion: Using the same threshold as our previous study, we have validated survivin CNR as a marker of good
prognosis in breast cancer in a large independent cohort. These findings provide robust evidence of the
importance of survivin CNR as a breast cancer biomarker, and its potential to predict outcome in tamoxifen-treated
patients.
Background
Personalised medicine, whereby individuals receive tai-
lored therapeutic regimens based on individual patient
and tumour characteristics, is now felt to be an achiev-
able goal. Effective implementation of personalised can-
cer therapeutic regimes, however, depends upon the
successful identification and translation of informative
biomarkers to aid clinical decision-making [1]. The role
of immunohistochemistry (IHC) within this arena is
most likely to involve predictive biomarker development,
as highlighted by the classical success of both estrogen
receptor (ER) and Her2 in breast cancer, which predict
response to tamoxifen and trastuzumab, respectively.
Survivin (encoded by the gene, BIRC5), a member of the
inhibitor of apoptosis protein family, is a multifunctional
protein implicated in a number of cellular processes
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h a sb e e np r o p o s e da sap r o m i s i n gt u m o u rb i o m a r k e r
mainly due to work using serial analysis of gene expression
(SAGE), which revealed that survivin was the fourth most
highly expressed transcript in a number of common can-
cers, but was rarely present in normal terminally-differen-
tiated tissues [3]. Multiple studies in several different
tumour types have investigated the prognostic value of
survivin [2]; however, many IHC-based studies have been
hampered by a failure to reach a consensus regarding how
survivin staining should be interpreted. Principally, discor-
dance has focused on whether examination of the cyto-
plasmic fraction, nuclear fraction or both provide more
useful information. Using IHC or subcellular fractionation,
two pools of survivin have been located (nuclear and cyto-
plasmic). These different pools are immunochemically and
functionally different and are independently modulated
during cell cycle progression [4].
Although it exhibits a high degree of tumour-specific
expression [3,5], and is one of the 16 cancer-related
genes represented in the Oncotype DX assay [6], the
role of survivin as a breast cancer biomarker has
remained the subject of much debate (1). Previous stu-
dies of survivin expression measured using qRT-PCR or
IHC in primary breast cancer have reported that it is
either prognostically irrelevant [7-9], or associated with
improved [10] or adverse outcome [11-13]. Such discor-
dant results could perhaps be explained by the fact that
these studies did not account for subcellular localisation
of survivin. Survivin is often simultaneously expressed in
both the cytoplasm and the nucleus, making manual
analysis of IHC difficult; however, the introduction of
digital imaging devices and computer-assisted image
analysis has provided a major advance towards quantita-
tive description of IHC signals [14].
We previously applied automated quantitative algo-
rithms to analyse survivin IHC data and demonstrated
that increased expression of nuclear, as opposed to cyto-
plasmic, survivin was associated with a decreased overall
survival (OS) and breast cancer-specific survival (BCSS)
[15]. A high cytoplasmic-to-nuclear ratio (CNR) was
associated with low grade, hormone receptor positivity
a n di m p r o v e dO Sa n dB C S S .M u l t i v a r i a t ea n a l y s i s
demonstrated that a high CNR (>5) was an independent
predictor of a prolonged survival [15].
This was the first study to examine the relationship
between survivin CNR and outcome and is consistent
with the hypothesis that nuclear and cytoplasmic survi-
vin fractions have different biological functions [4].
These earlier findings suggested that nuclear survivin is
a marker of poor prognosis in breast cancer and that
automated analysis can be used to quantify nuclear sur-
vivin. However, given the large number of conflicting
studies previously reported [2], a validation study is
required. The aim of the current study was to use
advanced pattern recognition algorithms to validate sur-
vivin CNR as a prognostic biomarker in an independent
breast cancer dataset.
Methods
Patients
This study included 512 consecutive patients with pri-
mary invasive breast cancer treated and diagnosed at
Malmö University Hospital between 1
st January 1988
and 31
st December 1992 [16-18]. The median age at
diagnosis was 65 (range 27-96) years and median fol-
low-up time to first breast cancer event was 128 months
(0-207). Information regarding the date of death was
obtained from the regional cause-of-death registries for
all patients. Complete treatment data were available for
379 (76%) patients, 160 of whom had received adjuvant
tamoxifen. Twenty-three patients received adjuvant che-
motherapy. Two hundred patients received no adjuvant
systemic treatment. Ethical permission was obtained
from the Local Ethics Committee at Lund University
(Dnr 613/02), whereby informed consent was deemed
not to be required other than by the opt-out method.
Tissue microarray construction
TMAs were constructed using two 0.6 mm cores taken
from areas representative of invasive cancer and
mounted in a recipient block using a manual arraying
device (MTA-1, Beecher Inc, WI, USA) as previously
described [19]. TMA blocks were stored in Dept. of
Pathology in Malmö University Hospital, Sweden. TMA
sections were cut immediately prior to staining.
Immunohistochemistry
Sections (4 μm) were dried, deparaffinised and rehy-
drated through descending concentrations of ethanol.
Heat-mediated antigen retrieval was performed using
microwave treatment for 2 × 5 min in a citrate buffer
(pH 6.0), before being processed either in the Ventana
Benchmark system (Ventana Medical Systems Inc, AZ)
using pre-diluted antibodies to ER (Anti-ER, clone
6F11), progesterone receptor (PR) (Anti-PgR, clone 16)
and Her2 (Pathway CB-USA, 760-2694) or in the Dako
Techmate 500 system (Dako, Glostrup, Denmark) for
Ki-67 (1:200, M7240; Dako) and survivin (1:50, D-8
Santa Cruz, CA). ER, PR and Ki-67 were quantified
using a commercially available automated nuclear algo-
rithm (IHC-MARK; OncoMark Limited, Ireland), as pre-
viously described [20]. ER, PR and Ki-67 negativity was
defined as < 10% positively stained nuclei. Her2 staining
was evaluated according to a standard protocol (Her-
cepTest) and scored as 4 intensities (i.e. negative, weak,
moderate and strong), namely 0-3+; these scores were
divided into two groups, with negative to weak (0-2+)
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-) and strong (3+) overexpression
(Her2
+).
Image acquisition, management and analysis
The Aperio ScanScope XT Slide Scanner (Aperio Tech-
nologies, Vista, CA) system was used to capture whole
slide digital images with a 20× objective. Digital images
were managed using Spectrum (Aperio). Tumour and
stromal elements were identified using Genie (Aperio)
pattern recognition software and a quantitative scoring
model for both nuclear and cytoplasmic survivin was
developed using the positive pixel count algorithm
(Aperio).
Statistical analysis
Spearman’s Rho correlation was used to estimate the
relationship between duplicate cores from individual
tumours. Differences in distribution of clinical data and
tumour characteristics between samples with a high and
low survivin nuclear autoscore (SNAS) and CNR were
evaluated using the c
2 test. Kaplan-Meier analysis and
the log rank test were used to illustrate differences
between OS and BCSS according to survivin expression.
Cox regression proportional hazards models were used
to estimate the relationship to OS and BCSS of survivin,
patient age, lymph node status, tumour grade, Her2, PR,
and ER status in the patient cohort. For decision tree
analysis, all patients were randomly divided into 10 sub-
sets. A decision tree model was selected using a 10-fold
cross-validation approach. Ten consecutive decision tree
models were independently constructed using the SNAS
and CNR continuous output from 9 subsets. Prognostic
accuracy of each decision tree model was tested using
the remaining set of patients, with the model displaying
the highest accuracy being selected as the optimal
model for the dataset. All calculations were performed
using SPSS version 12.0 (SPSS Inc, Chicago, IL). A p-
value < 0.05 was considered statistically significant.
Results
Automated quantification of survivin protein expression
in breast cancer
The specificity of the anti-survivin antibody was con-
firmed in our previous study [15]. Following optimisa-
tion of the staining procedure, it was possible to
evaluate survivin protein expression in 70.1% (n = 359)
of the tumours represented on the TMA. To evaluate
our study for any potential selection bias, baseline clini-
copathological characteristics from both the evaluated
(“survivin known”) cohort (n = 359) and the unevaluated
(“survivin unknown”) cohort (n = 153) are presented in
Table 1. This illustrates that the clinicopathological
characteristics were well matched in both evaluated and
unevaluated cohorts.
In order to develop an accurate quantitative auto-
mated model of survivin expression, a pattern recogni-
tion algorithm developed in Genie (Aperio) was used to
identify tumour from stroma and slide background. This
algorithm was trained using five prospectively selected
patterns - 1) tumour positive, 2) tumour negative, 3)
stromal fibroblast and extracellular matrix, 4) lympho-
cytes and 5) slide background (Figure 1A). Following
manual annotation of the training set, the five patterns
were provided as an input for the pattern recognition
algorithm in order to select the optimum approach. Per-
formance of the pattern recognition algorithm was then
tested in 20 randomly selected tissue cores (validation
set). Comparison of automated quantification to manual
annotation at pixel level resolution within the validation
s e tr e v e a l e dt h a tt h ea u t o mated approach had an accu-
racy of 87.3%. Additional file 1 illustrates the training
and output from the pattern recognition algorithm.
The positive pixel count (Aperio) was then applied to
develop a quantitative scoring model for tumour-specific
nuclear and cytoplasmic survivin expression. A pseudo-
colour “mark-up” image was generated for each core as
the algorithm output (Figure 1B). The accuracy of the
algorithm was examined in high power fields (Figure
1B) and was deemed acceptable by a histopathologist.
The algorithm was used to calculate total survivin
intensity, as well as cytoplasmic and nuclear intensity
for each core. One of the issues to consider when exam-
ining staining intensity alone is that even a small frac-
tion of staining artifact can significantly alter intensity
values. Therefore, to reduce noise secondary to staining
artifact SNAS (which combines the product of percen-
tage positive nuclei and nuclear intensity) was proposed
as an alternative automated scoring model for evaluating
nuclear survivin expression. A combined percentage and
intensity autoscore was calculated for both nuclear and
cytoplasmic survivin expression, as previously described
[15]. A strong correlation was evident between duplicate
cores from individual tumours for nuclear percentage
(Spearman’s Rho = 0.350; p < 0.001), nuclear intensity
(Spearman’s Rho = 0.479; p < 0.001), cytoplasmic per-
centage (Spearman’s Rho = 0.620; p < 0.001) and cyto-
plasmic intensity (Spearman’s Rho = 0.619; p < 0.001),
indicating a homogeneous pattern of expression. As
tumours were arrayed in duplicate, the maximum value
for each tumour was used for further analysis.
Nuclear, as opposed to cytoplasmic, survivin correlates
with outcome in breast cancer
We previously described a relationship between the CNR
of survivin and patient outcome [15]; however, the rela-
tionship between nuclear and cytoplasmic survivin
expression within individual tumours was not investi-
gated. Comparison of nuclear and cytoplasmic autoscores
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between maximum nuclear and cytoplasmic autoscore
(Spearman’s Rho = 0.753; p < 0.001), suggesting that
nuclear and cytoplasmic expression co-exist. In an
attempt to further evaluate the relationship between
nuclear and cytoplasmic survivin expression, patients
were divided into groups based on SNAS centiles (Figure
1C). This revealed a close relationship between nuclear
and cytoplasmic survivin. When nuclear survivin was
low, cytoplasmic survivin was also low; likewise, when
nuclear survivin was high, cytoplasmic survivin was also
high. However, a divergence between the two measures
in the mid range values suggests that a ratio such as the
CNR may be useful.
Decision tree analysis was then used to examine the
prognostic role of nuclear and cytoplamic survivin expres-
sion. Using a 10-fold cross-validation approach, the nor-
malised importance of SNAS, survivin cytoplasmic
Table 1 Clinical and tumour characteristics of evaluated cohort (n = 359) and entire cohort on TMA (n = 512) stratified
according to survivin nuclear autoscore (SNAS) and cytoplasmic-to-nuclear ratio (CNR) of survivin protein expression.
Entire Cohort Evaluated Cohort Evaluated Cohort
(n = 512) (n = 359) (n = 359)
Known Unknown p value SNAS < 4.26 SNAS > 4.26 p value CNR < 5 CNR > 5 p value
(n = 359) (n = 153) (n = 201) (n = 158) (n = 198) (n = 161)
Age (Years)
Median (Range)
< median (25-65) 53(49.1) 175(48.7) 0.520 98(48.8) 77(48.7) 0.541 99(50) 76(47.2) 0.598
> median (65-96) 55(50.9) 184(51.3) 103(51.2) 81(51.3) 99(50) 85(52.8)
Tumour Size
0 - 20 mm 255(71.6) 84(79.2) 0.119 148(73.6) 107(69) 0.340 134 (68.7) 121(75.2) 0.180
> 21 mm 101(28.4) 22(20.8) 53(26.4) 48(31) 61(31.3) 40(24.8)
Unknown 3 3 3
Nodal status
N0 203(63.6) 66(67.3) 0.502 110(62.1) 93(65.5) 0.537 118(65.9) 85(60.1) 0.337
N1+ 116(36.4) 32(32.7) 67(37.9) 49(34.5) 61(34.1) 55(39.2)
Unknown 40 19 19
NHG
I&II 237(66.2) 73(67.6) 0.788 145(72.5) 92(58.2) 0.005 119(60.1) 118(73.7) 0.007
III 121(33.8) 35(32.4) 55(27.5) 66(41.8) 79(39.9) 42(26.2)
Unknown 1
ER status
ER <10% 81(22.9) 25(23.8) 0.843 40(20.2) 41(26.3) 0.176 53(27.1) 28(17.7) 0.038
ER >10% 273(77.1) 80(76.2) 158(79.8) 115(73.7) 143(72.9) 130(82.3)
Unknown 5 2 2
PR Status
PR <10% 151(42.7) 50(47.6) 0.368 82(41.4) 69(44.2) 0.595 89 (45.4) 62(39.2) 0.243
PR >10% 203(57.3) 55(52.4) 116(58.6) 87(55.8) 107(54.6) 96(60.8)
Unknown 5 2 2
Ki-67
< 10% 128(27.8) 35(37.2) 0.926 82(43.9) 46(30.3) 0.010 55(29.2) 73(48.3) <0.001
> 10% 211(62.2) 59(62.8) 105(56.1) 106(69.7) 133(70.7) 78(51.6)
Unknown 20 10 10
Her2 IHC
Normal/weak (0 - 2
+) 285(80.5) 81(77.1) 0.451 166(83.9) 119(76.3) 0.075 149(76.1) 136(86.1) 0.018
Overexpressed (3
+) 69(19.5) 24(22.9) 32(16.1) 37(23.7) 47(23.9) 22(13.9)
Unknown 5 2 2
Abbreviations: SNAS = Survivin Nuclear Autoscore, CNR = Cytoplasmic to Nuclear Ratio, N0 = node negative, N1+ = node positive, NHG = Nottingham Harris
Grade, ER = estrogen receptor, PR = progesterone receptor, Her2 IHC = Her 2 immunohistochemistry
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Page 4 of 12Figure 1 Automated quantification of survivin immunohistochemistry. (A) Representative areas from tumour positive, tumour negative,
tumour stroma, tumour stroma cells and slide background were selected as a training set to develop a pattern recognition algorithm. (B)
Examples of IHC (20X) showing nuclear and cytoplasmic expression of survivin and mark-up images with the corresponding output from the
automated quantification approach. The algorithm maps survivin expression by labelling nuclear expression in red and cytoplasmic expression in
orange and yellow. (C) Box-plot demonstrating relationship between survivin nuclear and cytoplasmic autoscores. (D) Bar chart showing
normalised prognostic importance of SNAS, CNR and survivin cytoplasmic autoscore, as defined by the decision tree classification and regression
trees.
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Page 5 of 12autoscore and CNR was computed in relation to BCSS
and OS (Figure 1D). SNAS was consistently the most
prognostic marker for OS and BCSS followed by CNR,
again suggesting an important prognostic role for nuclear
survivin.
Survivin nuclear autoscore is an independent predictor of
outcome
In our initial study, we reported no link between survi-
vin nuclear or cytoplasmic intensity and survival; how-
ever, an increased SNAS was associated with a reduced
BCSS [15]. Application of the same SNAS threshold (8)
in this cohort demonstrated no association between
SNAS and either BCSS (p = 0.123) or OS (p = 0.298).
However, univariate cox regression analysis of SNAS as
a continuous variable revealed an association between
SNAS and a decreased BCSS (HR 1.028, 95% CI 1.001-
1.056; p = 0.044). A decision tree model was thus
employed to identify the optimal threshold for SNAS in
this cohort (Figure 2A) and predicted 4.26 as an optimal
cut-off for automated SNAS (Additional file 2).
Kaplan-Meier analysis comparing low (n = 158) and
high (n = 201) SNAS, as defined by decision tree analy-
sis, revealed that a high SNAS was associated with
decreased OS (p = 0.003) and BCSS (p = 0.004) (Figure
2B). Cox univariate analysis demonstrated that SNAS
was a predictor of a reduced BCSS (HR 2.05, 95% CI
1.27-3.31, p < 0.001) and OS (HR 1.51, 95% CI 1.13-
2.01, p = 0.005). Multivariate Cox regression analysis
controlling nodal status, grade, ER status, PR status,
Her2 status, tumour size and age revealed that SNAS
was an independent predictor of OS (HR 1.68, 95% CI
1.22-2.32, p = 0.002) and BCSS (HR 1.84, 95% CI 1.10-
3.08, p = 0.02), along with lymph node status, grade and
age (Table 2). The relationship between SNAS and
other clinicopathological variables was also examined
(Table 1). A high SNAS was associated with high grade
(p = 0.005) and Ki-67 positivity (p = 0.010). No relation-
ship was evident between SNAS and patient age, nodal
status, hormone receptor expression or Her2 status.
Cytoplasmic-to-nuclear ratio of survivin is an independent
predictor of disease-specific survival
Having demonstrated a significant relationship between
SNAS and survival, the CNR of survivin protein expres-
sion was examined. The initial study used a non-super-
vised approach to identify a CNR of 5 to divide patients
into groups with low and high CNR [15]. Decision tree
models were again used to identify an optimal threshold
for CNR. This model predicted a cut-off of 4.87 (Figure
2C) as the optimal threshold for CNR, which correlated
well with the value used in the previous study [15].
There was an excellent correlation between low CNR
a n dh i g hC N Rd e f i n e du s i n gat h r e s h o l do f4 . 8 7o r5
(R = 0.983, p < 0.001). Patients were thus divided into
groups of low and high CNR using 5 as a threshold on
the automated continuous scores (Additional file 2).
Forty-nine percent (n = 161) of tumours had a CNR
greater than 5. Kaplan-Meier analysis of OS and BCSS
revealed that a survivin CNR of < = 5 was associated
with a reduced BCSS (p = 0.005) but had no effect on
OS (p = 0.187) (Figure 2D). Univariate Cox regression
analysis (Table 2) confirmed the relationship between
CNR and an improved BCSS (HR 0.49, 95% CI 0.29-
0.81, p = 0.006). Multivariate analysis controlling for
age, tumour size, nodal status, grade, ER, PR and Her2
status revealed that an increased survivin CNR was a
predictor of a prolonged BCSS (HR 0.47, 95% CI 0.27-
0.82, p = 0.008), along with tumour grade and lymph
node status (Table 2). The relationship between survivin
CNR and other clinicopathological variables was also
examined. An increased survivin CNR was associated
with ER-positive (p = 0.045), low grade (p = 0.007), Ki-
67-negative (p = 0.001) and Her2-negative (p = 0.026)
tumours (Table 1).
Nuclear survivin expression predicts outcome in ER-
positive tumours
Given the previously described relationship between
increased CNR and ER positivity, we proceeded to
examine the relationship between nuclear survivin and
outcome in ER-positive patients. Nuclear survivin was
measured as an increased SNAS or a low CNR. A low
CNR (<5) was associated with a decreased BCSS (p =
0.029) in ER-positive patients (n = 273) (Figure 3A), an
effect that was not evident in ER-negative (n = 81)
patients (p = 0.062). A low CNR (<5) was also asso-
ciated with a trend towards a decreased OS (p = 0.062)
in ER-positive patients (Figure 3A). A high SNAS was
also associated with a reduced BCSS (p = 0.005) and OS
(p = 0.013) (Figure 3B) in ER-positive patients and a
reduced BCSS (p = 0.036), but not OS (p = 0.136) in
ER-negative patients.
Having demonstrated that nuclear survivin predicts
outcome in ER-positive patients, we proceeded to exam-
ine its effect on ER-positive patients who received
tamoxifen (n = 125). This revealed that a high SNAS
was associated with a reduced OS (p = 0.006) and BCSS
(p = 0.013) (Figure 4A) in tamoxifen-treated ER-positive
patients. Likewise, a low CNR was associated with a
r e d u c e dO S( p=0 . 0 2 1 )a n dB C S S( p=0 . 0 1 8 )i nE R -
positive patients who received tamoxifen (Figure 4B).
Multivariate Cox regression analysis demonstrated that
neither SNAS (HR 1.87, 95% CI 0.71-4.88, p = 0.194)
nor CNR (HR 0.41, 95% CI 0.15-1.13, p = 0.087) were
independent predictors of BCSS in tamoxifen-treated
patients; however, a low CNR was an independent pre-
dictor of OS in tamoxifen-treated patients (HR 0.44,
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Page 6 of 12Figure 2 Survivin CNR and SNAS correlate with patient outcome. (A) Schematic view of the decision tree prognostic classification model
based on the continuous automated quantification of SNAS. Examples of breast cancer specimens with low and high SNAS, as defined by the
decision tree prognostic model, are also shown. (B) Kaplan-Meier estimation of OS and BCSS comparing patient with high and low SNAS, as
defined by the decision tree prognostic model. (C) Schematic view of the prognostic classification model based on the continuous automated
quantification of survivin CNR and examples of breast cancer specimens with low and high CNR, as defined by the decision tree prognostic
model. (D) Kaplan-Meier estimation of OS and BCSS comparing patient with high and low CNR, as defined by the decision tree prognostic
model.
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(Table 3).
Discussion
High-throughput screening methodologies, particularly
genomic and transcriptomic profiling have revolutio-
nised the scientific approach to highly complex diseases
such as breast cancer [21]. The potential now exists to
gather increasingly complex biomedical and molecular
data to develop personalised therapeutic regimens. Per-
sonalised medicine requires the discovery and applica-
tion of unambiguous prognostic, predictive and
pharmacodynamic biomarkers to inform therapeutic
decisions [1,22]. One of the disappointing aspects of the
post-genomic era is that while a plethora of putative
biomarkers have undergone preliminary clinical evalua-
tions, only a small minority have received regulatory
approval for clinical use. This attrition rate has been
attributed to the lack of validation studies. Here, we
describe the validation of survivin CNR in a large conse-
cutive breast cancer cohort.
Table 2 Cox univariate and multivariate analysis of
recurrence free and overall survival in entire cohort
BCSS OS
HR (95%CI) p RR (95%CI) p
All patients (n = 359)
SNAS Univariate Univariate
low 1.00 1.00
high 2.05(1.27 - 3.31*) < 0.001 1.51(1.13 - 2.01) 0.005
SNAS Multivariate* Multivariate*
low 1.00 1.00
high 1.84(1.10 - 3.08) 0.020 1.68(1.22 - 2.32) 0.002
All patients (n = 359)
CNR Univariate Univariate
low 1.00 1.00
high 0.49(0.29 - 0.81) 0.006 0.85(0.64 - 1.13) 0.267
CNR Multivariate* Multivariate*
low 1.00 1.00
high 0.47(0.27 - 0.82) 0.008 0.73(0.53 - 1.02) 0.067
* Multivariate analysis included adjustment for grade, age, nodal status, ER
status, PR status
Her2 and tumour size
Figure 3 Increased nuclear survivin predicts outcome in ER-positive patients. (A) Kaplan-Meier estimation of OS and BCSS comparing ER-
positive patients with high and low CNR, as defined by the decision tree prognostic model. (B) Kaplan-Meier estimation of OS and BCSS
comparing ER-positive patients with high and low SNAS, as defined by the decision tree prognostic model.
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Page 8 of 12Figure 4 Increased nuclear survivin predicts outcome in ER-positive patients. Kaplan-Meier estimation of OS and BCSS in ER-positive,
tamoxifen treated patients stratified according to (A) CNR and (B) SNAS.
Table 3 Cox regression analysis of recurrence free- and overall survival in ER positive patients
BCSS OS
ER Positive (n = 285) HR (95% CI) p HR (95% CI) p
SNAS Univariate Univariate
low 11
high 2.01(1.14 - 3.54) 0.014 1.57(1.14 - 2.16) 0.005
SNAS Multivariate Multivariate
low 11
high 1.38(0.71 - 2.66) 0.335 1.36(0.90 - 2.06) 0.140
SNAS Multivariate + treatment adjusted Multivariate + treatment adjusted
low 11
high 1.87(0.71 - 4.88) 0.194 1.92(0.98 - 3.78) 0.055
CNR Univariate Univariate
low 11
high 0.52(0.29 - 0.94) 0.032 0.85(0.61 - 1.13) 0.320
CNR Multivariate Multivariate
low 11
high 0.805(0.52 - 1.22) 0.315 0.54(0.27 - 1.10) 0.094
CNR Multivariate + treatment adjusted Multivariate + treatment adjusted
low 11
high 0.41(0.15 - 1.13) 0.087 0.44(0.23 - 0.87) 0.018
* Multivariate analysis included adjustment for grade, age, nodal status, PR status, Her2 and tumour size
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sis, we demonstrated that nuclear, as opposed to cytoplas-
mic, survivin is a major predictor of outcome in breast
cancer. Increased SNAS was associated with a reduced
BCSS and OS (Figure 2), while an increased CNR was asso-
ciated with an improved BCSS (Figure 2), confirming the
relationship between nuclear survivin and poor outcome.
Multivariate analysis confirmed that both measures were
independent predictors of outcome (Table 2), thus validat-
ing our previous findings associating nuclear survivin with
a poor outcome [15]. Although the threshold used to
dichotomise patients based on high versus low SNAS
(4.26) was different to our initial study, decision tree analy-
sis confirmed a threshold of 5 for CNR in this study also,
thus validating our initial analysis in a second cohort using
an identical threshold for survival analysis. High CNR was
also associated with a number of good prognostic features
including ER positivity and low grade (Table 1). Conver-
sely, a high SNAS was associated with high grade, Ki-67
positive tumours (Table 1), suggesting that nuclear survivin
is associated with a proliferative phenotype.
T h e s ed a t af u r t h e rv a l i d a t et h eh y p o t h e s i st h a tt h e
nuclear and cytoplasmic fractions of survivin have differ-
ent biological roles [23] and support an important role
for nuclear-cytoplasmic transport of survivin in tumour-
igenesis and disease progression [24,25]. Nucleo-cyto-
plasmic shuttling of survivin is controlled by an
evolutionary conserved Crm1-dependent nuclear export
signal (NES). A number of groups have demonstrated
that inhibition of this signal abrogates the anti-apoptotic
effect of survivin, while maintaining its mitotic effect
activity, suggesting that increased levels of nuclear survi-
vin could lead to a proliferative aggressive phenotype
[24,26,27].
As mentioned previously, the prognostic relevance of
survivin in breast cancer is a controversial issue and a
number of smaller qualitative IHC-based studies have
produced conflicting results. It is possible that the quan-
titative measurement of survivin (either by ELISA or
image analysis) is necessary for its utilisation as a breast
cancer biomarker. Interestingly, our initial study [15], as
well as those of Span et al. [28] and Ryan et al. [11], used
quantitative methods to evaluate survivin expression and
found similar results. The added benefit of our approach
is that formalin-fixed paraffin-embedded materials, as
opposed to frozen tissue specimens, can be used.
In this study, we were also able to perform subset ana-
lysis and demonstrate that a low CNR predicts poor
outcome in tamoxifen-treated patients (Table 3). A
number of groups have demonstrated that survivin is
associated with tamoxifen resistance in vitro [29,30].
Span et al [28] reported that increased levels of survivin
expression (quantified using ELISA) were associated
with a good response to chemotherapy, but a poor
r e s p o n s et oe n d o c r i n et h e r a p y .W ew e r eu n a b l et o
examine response to chemotherapy in this study, as only
23 patients received adjuvant systemic chemotherapy.
Here, survivin expression was examined in 89 tamoxi-
fen-treated patients, which compares adequately with
Span et al w h oe x a m i n e ds u r v i v i ne x p r e s s i o ni n7 3
patients treated with tamoxifen [28] and adds further
evidence that survivin may play an important role in
anti-endocrine resistance. It should be acknowledged
that these patients did not participate in a prospective
randomised trial, and the predictive value of survivin
CNR in tamoxifen-treated patients should be validated
in such a setting.
These data add further evidence to the theory that inhi-
bition of survivin may be a viable therapeutic option. A
number of phase I and II trials evaluating small molecule
inhibitors, antisense nucleotides and immunotherapy tar-
geted against survivin are ongoing [31]. Our data suggest
that inhibition of nuclear, as opposed to cytoplasmic, sur-
vivin will render the best results, and that the combina-
tion of anti-survivin therapies and tamoxifen may be an
attractive therapeutic option in a subgroup of ER-positive
patients. Further studies will be required to shed light on
the value of nuclear and cytoplasmic survivin expression
as a surrogate markers of response to any new treatment,
with the image analysis solution presented here poten-
tially providing important information in this regard.
Conclusion
In conclusion, we have validated our previously pub-
lished method of quantitatively determining the expres-
sion of survivin via IHC. Our data add further evidence
to the hypothesis that the different sub-cellular pools of
survivin have distinct functions and increased levels of
nuclear survivin are associated with a proliferative phe-
notype. Additionally, we have demonstrated that nuclear
survivin may predict outcome for tamoxifen-treated
breast cancer patients. However, this will require further
validation in a prospective cohort. The quantitative
image analysis approach described here may be helpful
in further dissecting the debate surrounding the role of
survivin IHC as a prognostic marker in breast cancer
and may be particularly beneficial if ongoing trials of
anti-survivin therapies are successful.
Additional material
Additional file 1: Training and validation of survivin pattern
recognition algorithm. (A) Representative areas from tumour positive,
tumour negative, tumour stroma, and slide background were selected as
a training set to develop a pattern recognition algorithm. (B) Each area
was labelled according to the pattern it represents, to provide the
evolutionary pattern recognition algorithm with ground truth data to
calculate performance of candidate solutions, with the following colour
coding being used: tumour positive = red, tumour negative = blue,
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Page 10 of 12tumour stroma = green, slide background = cyan. (C) Representative
areas from tumour positive, tumour negative, tumour stroma and slide
background were selected as a validation set to develop a pattern
recognition algorithm. (D) Each area was labelled according to the
pattern it represents to provide ground truth data to the calculate
performance of the final solution for recognition of the following:
tumour = red, tumour stroma = green, slide background = yellow.
Additional file 2: Automated quantification of low and high scores
for SNAS and CNR. Original IHC images of representative tissue cores
with low and high CRN and SNAS patterns. Corresponding automated
output from Genie pattern recognition algorithm is shown in second
column.
Abbreviations
BCSS: breast cancer specific survival; CI: confidence interval; CNR:
Cytoplasmic-to-Nuclear ratio; ER: estrogen receptor; HR: hazard ratio; IHC:
immunohistochemistry; NES: nuclear export signal; OS: overall survival; PR:
progesterone receptor; qRT-PCR: quantitative real time polymerase chain
reaction; SAGE: serial analysis of gene expression; SNAS: Survivin Nuclear
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